Latest International Markets News

Biome Australia capped FY26 with record $23.9 million sales and its flagship probiotic topping Australian pharmacy charts. The company signed an onshore manufacturing deal and expanded its proprietary probiotic clinical trial internationally.

ReadCloud Limited’s June quarter saw a record $3.5m in cash receipts from its school businesses, driving 6% year-to-date growth despite exiting its Industry Training arm. The company forecasts over $1m uEBITDA for FY26 and is building momentum for FY27 expansion.

Biome Australia (ASX: BIO) edged close to breakeven in FY26, driven by $1.8 million in international sales across four markets and a 68% gross margin. The company is set to launch onshore manufacturing and a digital health platform to accelerate growth.

Locate Technologies’ Q4 FY26 update highlights a 54% surge in Locate2u revenue to NZ$1.20 million, driving normalised EBITDA into positive territory. AI integration accelerated product development and customer onboarding, while capital moves included a share buyback and royalty conversion.

Monvia Limited, an Australian SaaS provider for life insurers, is seeking to raise $17.5 million via an IPO on the ASX. The funds will support redemption of preference shares and fuel growth in existing and new markets.

PainChek has received a $1.123 million R&D tax incentive refund for FY2025, reinforcing its cash reserves and underpinning ongoing development of AI pain assessment algorithms and US market validation.

Terrain Minerals (ASX: TMX) delivered a strong June quarter update, confirming high-grade gold and silver mineralisation at its Smokebush flagship, progressing a maiden resource estimate at Lightning, and reporting broad rare earth and lithium anomalies at Lort River and Carlindie projects.

AFT Pharmaceuticals secures tentative FDA approval for Scomara cream to treat rare facial tumours but faces a US launch delay due to orphan drug exclusivity. The approval bolsters prospects in other markets where AFT expects competitive advantages.

Orthocell Limited has posted record revenue for FY2026, driven by strong sales growth of Remplir™ and Striate+™ products in Australia, the US, and new international markets, supported by a robust $44.1 million cash position.

Rua Bioscience has secured its largest export contract, committing to supply New Zealand-grown medical cannabis flower to a major UK distributor, projecting over NZ$10 million in revenue across two years.

ReNerve has locked in a flexible A$5 million convertible note facility with RiverFort, drawing an initial A$1.6 million to back its commercial push and US sales ramp-up.

SPC Global reported solid Q4 FY26 growth driven by domestic beverage sales and a 50.8% jump in international revenue, while a $100 million equity raise slashed net leverage and paved the way for improved cash flow in FY27.